MedTrace Logo

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

NCT02889874 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1167

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.

Conditions

  • Early Stage Breast Carcinoma

Interventions

RADIATION

Omission of radiation therapy

Omission of radiation therapy (adjuvant endocrine therapy only).

Sponsors & Collaborators

  • Breast International Group

    collaborator OTHER

  • ETOP IBCSG Partners Foundation

    collaborator NETWORK

  • Breast Cancer Trials, Australia and New Zealand

    lead OTHER

Principal Investigators

  • Heath Badger · Breast Cancer Trials, Australia and New Zealand

  • Boon H Chua, Prof · Prince of Wales Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-21
Primary Completion
2027-09-30
Completion
2028-04-30

Countries

  • Argentina
  • Australia
  • Chile
  • Ireland
  • Italy
  • New Zealand
  • Spain
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02889874 on ClinicalTrials.gov